Business
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients GlobeNewswire September 09, 2024 Beamion LUNG-1, Phase Ib met its
![Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients](https://phuketnews.easybranches.com/uploads/news/2024/09/boehringer-s-zongertinib-shows-encouraging-efficacy-and-tolerability-profile-in-previously-treated-her2-mutated-lung-cancer-patients.jpg)
GlobeNewswire
September 09, 2024
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1